NCT02819596 2024-11-04
CALYPSO
Queen Mary University of London
Phase 2 Completed
Clinical Trials
7 trialsNCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT00378482 2024-08-22
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Phase 2 Completed
NCT02762006 2024-03-18
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT01975831 2022-10-12
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02626130 2022-07-07
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT00372853 2012-06-06
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
AstraZeneca
Phase 1 Completed